Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2015 Q1- Text added to 2015 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
8th grade Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
8th grade Avg
|
New words:
adalimumab, alfa, American, AMPLE, Andexanet, anticoagulant, Antidote, Bolivar, castration, continuum, decade, decided, devaluation, diagnosed, DMC, ELd, exploratory, faster, French, FXa, HCC, hepatocellular, HR, infusion, killer, Labour, Ld, line, lock, malignant, Member, mesylate, OCI, onset, Paraplatin, PFS, plasma, Portola, predetermined, profile, rank, refractory, registered, relapsed, senior, smaller, SQ, statistical, suggest, tender, thrombin, TRIO, unbound, unrealized, unsecured, variation, Venezuelan
Removed:
CHMP, cure, meslylate, NDA, patient, represented
Valuein 2015 Q1 filing- Value in 2015 Q2 filing
Original filings
Filing view